Replies to post #74636 on PharmaCyte Biotech Inc (PMCB)

[1234jklm]

They agreed to 10% and now its 50%


Austrianova will receive 50% of any other financial and non-financial consideration received from the Company’s sublicensees of the Cell-in-a-Box® technology.

We get the right to buy ciab but what if we can't afford it?

And even if we buy it they get 50% of anything we make from it.

But we already have a license and it's much better and cheaper.

We paid 2million for a license and now they want to dump it for something not as good.

It looks like Shareholders are getting screwed if this goes ahead.

[tulla236a]

this is the way i see it.

pmcb can buyout all rights to ciab within a 5 year period. if someone wants buy all rights to ciab, they do it through pmcb. austrianova will get 4% for the mj, diabetes and assets and 50% of all other ciab uses. so each segment of ciab has to have a separate value place on it. so we are gaining 50% of all other uses that we didn't have before, stem cell?

or

pmcb can sublicenses the diabetes, pc, and mj part and austrianova will get 20% of the sublicensees gross sales with the potential to get 50% of their first 2%.

if i am reading this right, we will get more on an all out rights buyout.

[1234jklm]

Where did you get this term sheet tulla?

I've only got the press release.